Roche to Acquire GenMark Diagnostics for $1.8 Billion in All-Cash Deal

Roche to Acquire GenMark Diagnostics for $24.05 Per Share in All-Cash TransactionRoche will fully acquire GenMark Diagnostics at a price of $24.05 per share in an all-cash transaction, representing a total equity value of approximately $1.8 billion on a fully diluted basis. Upon completion of the acquisition, GenMark’s core operations will continue at its current location in Carlsbad, California, USA. GenMark Diagnostics' portfolio of syndrome test kits will complement Roche's existing molecular diagnostics offerings, while Roche's global network will expand the reach of GenMark's products.

GenMark’s ePlex system enhances laboratory efficiency through a streamlined order-to-report workflow and improves patient outcomes by enabling rapid diagnosis of symptoms. Infectious diseases are a leading cause of death globally, and early detection of infection has been shown to improve patient outcomes and support key hospital initiatives such as antibiotic stewardship and reducing hospital stays. GenMark’s Respiratory Pathogen Panel identifies the most common viral and bacterial microorganisms associated with upper respiratory infections, including SARS-CoV-2, complementing Roche's broad portfolio of COVID-19 diagnostic solutions.

GenMark Diagnostics, a leading provider of multiplex molecular diagnostic solutions, aims to enhance patient care, improve critical quality metrics, and reduce the overall cost of care. GenMark's eSensor XT-8 and ePlex systems utilize GenMark's proprietary eSensor detection technology, designed to support a wide range of molecular diagnostic sample-to-answer testing through compact, easy-to-use workstations and self-contained disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and meet a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.